as to Chief welcome the am am our our to requesting morning complete and we get QX and everyone, XXXX this our with I FDA the Hello, operator. Officer. happy you, and response clinical Kellen, here. we to Much been submit call. our joined performed this Dr. of has conference plan hard being Thank us I Scott report Financial work Chief to that Kirsten Medical morning to lifting speak this week. Gruis, our finalized Officer hold is
leading bag light IV storage our material conclusions part halting one was that that cause FDA parts. two The independent such durations, confirmed of administered. of to part temperature exposure. the the study consisted being the April. study. case the in worst actual and laboratory and at completed the our change of two was drug the was the performed as one believe in This We varying the an simulated And data use events hospital hypotensive a in from enrollment scenarios effects in evaluated of Part requested new of
means likely to required Phase the no the micrograms X substantially results were study IV consistent new two kg special part one to last we results the dose IV with fall our part with point IV the completed year, that that match of per for that part by dosing I administration the FDA. We in-use this favorable of IV bag from instructions of DMXXX. Results would out levels. which where be X.X will consistent one, decision handling the to were testing there hope in also a were contribute stroke we trial proposed revising consistency of
proposed planned everyone, Phase subcutaneous three label conducted PVC suggest was or ensuing remind dosing trial protocol. ascending there XC under study to human the the report have a testing, are a X.X, the very I'm we used not kg. per pleased administered no in in request X.XXX the trial just dose recently volunteers ReMEDyX using initiated changes IV and to bags Phase single XC the study to open did FDA And healthy X.X weeks that we even of This be DMXXX planned though study Australia. completed microgram to and in also at
hold supporting range. IV results clinically for give the stroke trial. to hypertension from our data proposed with have study in additional concentration The micrograms reach seen therapeutic kg this significant results X.X as further and per safe, acute proposed Phase and are micrograms The kg data blood that that minimize risk ReMEDyX response. DMXXX, X.X be desired of a Phase dose revised well human ischemic XC the to that would X range will confidence generally results prior and for is achieved IV of tolerated the us our per as dose targeted confirmed reached level will included clinical DMXXX revision be These
support and trial. resulting engage demonstrate prior the that believe the to in to study new also safety ReMEDyX provide this will data our and and and patient and commitment our investigators greater comfort study We for principal sites
providing the unexpected Phase believe events. of of have a the fully our for year's the adequate will identified hypertensive cause to with XC our the we hypotensive last that As DMXXX. cautiously to the per optimistic We FDA of of cause support be data optimistic prior to All hold. result and the we are in, results that the tolerability safety the work, will analysis micrograms events we study all and proposed dose support further the this of allow kg revision demonstrate clinical and of the X.X are lift IV this FDA
we team With next I'm pivotal expected be Once a place the the and update positive, relaunching an year, execute we ReMEDyX back in we will steps trial, response expansion if past team the of from right trial. for trial. hear ReMEDyX the have the on this is we provide which confident that believe the our FDA, the to will timing
on David We He of DiaMedica was He our outside my he the actually is his have advisors our key him been purchase have NASDAQ trusted David past the to Officer. of DMXXX Wambeke tell advancing also committed understanding Business to years. stock. most the And you to DMXXX relevant as over of over grateful life XX-years capital investment our and brings experience addition relationships markets, Dave the one team our team. recent well, an Investor has can part communities. public of banker M&A DiaMedica. as initial also offering Chief management programs. brings extensive our sciences, $XXX,XXX across reliable common and with as five of has with Relations biotech We're of XXXX recently and on of expanded lead and
highlights. to Kellen financial I the would turn the now to Scott review call to like
